Fiduciary Group LLC Has $2.54 Million Stock Holdings in Kenvue Inc. (NYSE:KVUE)

Fiduciary Group LLC grew its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 82.0% in the 4th quarter, Holdings Channel reports. The fund owned 117,881 shares of the company’s stock after buying an additional 53,129 shares during the period. Fiduciary Group LLC’s holdings in Kenvue were worth $2,538,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in KVUE. CWM LLC raised its position in Kenvue by 1,521.1% in the third quarter. CWM LLC now owns 12,969 shares of the company’s stock valued at $260,000 after purchasing an additional 12,169 shares during the last quarter. AE Wealth Management LLC bought a new position in Kenvue in the 3rd quarter valued at approximately $619,000. IFP Advisors Inc acquired a new stake in Kenvue during the 3rd quarter worth approximately $38,000. Global Retirement Partners LLC bought a new stake in Kenvue during the 3rd quarter worth approximately $28,000. Finally, SG Americas Securities LLC acquired a new position in Kenvue in the 3rd quarter valued at approximately $1,062,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

KVUE has been the topic of a number of recent research reports. JPMorgan Chase & Co. cut their price target on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a report on Friday, February 9th. William Blair assumed coverage on Kenvue in a report on Wednesday, April 3rd. They set a “market perform” rating on the stock. Sanford C. Bernstein began coverage on Kenvue in a research note on Thursday, April 11th. They issued an “underperform” rating and a $18.00 price target for the company. Royal Bank of Canada lowered their price objective on Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a research report on Friday, February 9th. Finally, The Goldman Sachs Group began coverage on shares of Kenvue in a research report on Friday, March 1st. They set a “neutral” rating and a $20.00 target price for the company. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Kenvue currently has a consensus rating of “Hold” and an average price target of $24.85.

Kenvue Price Performance

Kenvue stock traded down $0.16 during trading on Friday, hitting $18.86. The stock had a trading volume of 15,454,689 shares, compared to its average volume of 13,458,618. The stock’s 50 day moving average is $19.84 and its two-hundred day moving average is $20.13. Kenvue Inc. has a 1 year low of $17.82 and a 1 year high of $27.80. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.12 and a quick ratio of 0.78.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, February 8th. The company reported $0.31 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.03. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. The firm had revenue of $3.67 billion for the quarter, compared to analysts’ expectations of $3.78 billion. The business’s quarterly revenue was down 2.7% compared to the same quarter last year. Analysts predict that Kenvue Inc. will post 1.15 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 22nd. Investors of record on Wednesday, May 8th will be issued a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 4.24%. The ex-dividend date is Tuesday, May 7th.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.